AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of annual sales of $3 billion to $5 billion for the 3-in-1 inhaler. Two phase ...
Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...
Hosted on MSN
AstraZeneca’s Breztri Therapy Meets Primary Goals In Late-Stage Trials To Treat Asthma: Retail’s Positive
AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination therapy Breztri Aerosphere in patients with uncontrolled asthma. Breztri ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback